Abstract
The immunocomplex presence has been associated with this complication in both kidney and heart transplantation, its etiology in the setting of liver transplantation remains unknown. We performed a retrospective study, including patients who underwent liver transplantation (n=373) during the period between 2000 and June 2013, at the "12 de Octubre” Hospital Two groups were defined: group 1 (positive inmunocomplexes) and group 2 (negative immunocomplex). Mean age was 54 ± 10,5 in group 1 vs 54 ± 10,5 in group 2 (p=NS). 75% and 68.5% of patients were male in groups 1 and 2 respectively. The rate of hepatocellular carcinoma was 16.1% in group 1 vs 27.6% in group 2 (p 0.007), while HCV infection was 38.5% in group 1 and 54.7% in group 2 (p 0.002). No statistically significant differences were found related to blood product transfusion, ICU or ward stay, MELD score. Pretransplant portal thrombosis was 13.2% in group 1 vs 16% in group 2 (p 0.05). However, there were no statistically significant differences regarding post-transplant arterial thrombosis (4.2% group 1 vs 3.4% group 2; p 0.63) or in relation to post-transplant portal thrombosis, which was 1% in group 1 and 1.1% in group 2 (p 0.95). Actuarial survival rates at 1, 3 and 5 years for group 1 were 85.6%, 76.6%, and 71.3% respectively, while for group 2 they were 80.7%, 72.9% and 66.3%, (p 0.109). In our series, immunocomplex presence has not been confirmed to be a relevant factor in the development of graft vascular thrombosis in liver transplantation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.